Apogee Therapeutics, INC 10-Q quarterly reports

Apogee Therapeutics reports positive clinical data for its lead candidate, zumilokibart, and progress on its planned acquisition by AbbVie, while navigating substantial R&D expenses.

Apogee Therapeutics, Inc. reported a net loss of $74.1 million for the first quarter of 2026, with significant investments in research and development for its inflammatory and immunology programs.

Apogee Therapeutics reports increased net loss in Q3 2025 but highlights positive clinical data for APG777 and significant capital raise post-quarter end.

Apogee Therapeutics announced positive interim results for its lead programs APG777 and APG808, demonstrating favorable efficacy and extended half-life profiles.

Apogee Therapeutics details its financial performance for Q1 2025, highlighting progress in clinical trials and strategic collaborations.

Apogee Therapeutics reports a net loss of $49 million for Q3 2024, alongside updates on its clinical programs and financial position.

Apogee Therapeutics, a clinical-stage biotech company, released its 10-Q filing for the quarter ended June 30, 2024, detailing financial results and providing updates on its clinical programs.

Apogee Therapeutics reports a net loss of $32.1 million for the first quarter of 2024, alongside significant progress in clinical development and a strong cash position.